Sid Sijbrandij

That's right.

The combination of treatments, there's very little incentive for pharma companies to kind of spend a billion dollars.

It's now a billion dollars for a successful trial.

They spend a billion dollars for an approved medicine to research a combination of drugs.

So there's no incentive.

So all you see on the market are these drugs taken in isolation.

And doctors are reluctant to combine them because it's never been done before.

But if you look at the first principles, you can say, hey, these treatments are probably okay to combine.

What you don't want to do is have like combined two things that both hit the kidneys because your kidneys are going to be over capacity and that's not good.

Mm-hmm.

So every time we combine treatments, I have, for example, a pathologist in my tumor board to look at like, hey, can we combine these things?

And we also look at my own markup, including genetics, but also histochemistry, where you color slides in and we do multiplexing so we can color multiple things.

For example, I told you I went to China three months ago.

And I did that to get the first B7H3 scan available to me.

And because of what we learned there, we were able to kind of change the development of one of the drugs I'm developing to remedy what we saw.

We saw in China that I have higher B7H3 expression in the liver than any one of the 20 patients they saw before.

And we decided to combine that medicine with something that's rarely expressed in the liver.

So it's not gonna destroy my liver going forward.

So you gotta be kind of, what I'm trying to do is kind of be first principles about it instead of kind of relying on evidence for the ability to combine because that evidence, it doesn't exist because no one has the incentive to do that.

Right.